[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC).
• Resistance to EGFR-TKIs is a significant clinical challenge.
• Immune checkpoint inhibitors (ICIs) have revolutionized advanced NSCLC treatment but show limited efficacy in EGFR-mutated NSCLC.

Approach:

• This review summarizes clinical data on ICI efficacy in EGFR-mutated NSCLC.
• It analyzes the distinct tumor microenvironment (TME) characteristics of EGFR-mutated tumors.
• Key TME features examined include PD-L1 expression and tumor mutational burden (TMB).

Key Points:

• EGFR-mutated NSCLC exhibits heterogeneous PD-L1 expression and TMB compared to wild-type tumors.
• The unique TME in EGFR-mutated NSCLC influences ICI response.
• Understanding these TME differences is crucial for optimizing immunotherapy.

Conclusions:

• Further exploration is needed to determine the suitability and optimal use of ICIs in EGFR-mutated NSCLC.
• Deciphering the unique TME of EGFR-mutated NSCLC is essential for improving treatment strategies.
• Novel approaches may be required to enhance ICI efficacy in this patient population.